Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Capital Expenditures: 2015-2025

Historic Capital Expenditures for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to -$991,309.

  • AC Immune's Capital Expenditures fell 408.20% to -$991,309 in Q3 2025 from the same period last year, while for Sep 2025 it was -$632,191, marking a year-over-year decrease of 159.45%. This contributed to the annual value of $657,517 for FY2024, which is 27.19% down from last year.
  • Latest data reveals that AC Immune reported Capital Expenditures of -$991,309 as of Q3 2025, which was down 120.03% from -$450,543 recorded in Q2 2025.
  • In the past 5 years, AC Immune's Capital Expenditures registered a high of $4.9 million during Q4 2021, and its lowest value of -$991,309 during Q3 2025.
  • For the 3-year period, AC Immune's Capital Expenditures averaged around -$24,951, with its median value being -$216,233 (2023).
  • As far as peak fluctuations go, AC Immune's Capital Expenditures skyrocketed by 76.76% in 2022, and later slumped by 499.17% in 2025.
  • Over the past 5 years, AC Immune's Capital Expenditures (Quarterly) stood at $4.9 million in 2021, then crashed by 48.71% to $2.5 million in 2022, then slumped by 36.00% to $1.6 million in 2023, then declined by 25.12% to $1.2 million in 2024, then crashed by 408.20% to -$991,309 in 2025.
  • Its Capital Expenditures was -$991,309 in Q3 2025, compared to -$450,543 in Q2 2025 and -$402,635 in Q1 2025.